ArticleFrontiers in immunology2026
The role of NEDD4-mediated ubiquitination of AQP5 in allergic rhinitis: implications for nasal mucosal barrier function.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic rhinitis (AR) pathology is mainly due to disruption of the nasal epithelial barrier, but the role of aquaporin 5 (AQP5) is not fully understood. We propose that the E3 ubiquitin ligase NEDD4 is responsible for the degradation of AQP5 and thus affects barrier homeostasis in AR. Methods: Human nasal epithelial cells and ovalbumin-induced Sprague-Dawley rats were used as Results: We demonstrated that NEDD4 directly interacts with and ubiquitinates AQP5 at lysine 257, leading to its proteasomal degradation. NEDD4 was upregulated by IL-13, and this upregulation did not alter AQP5 mRNA levels. Decreasing NEDD4 or increasing AQP5 expression restored barrier integrity and inhibited MUC5AC and IL-6/IL-8 synthesis and concomitantly suppressed p38 MAPK activation; this suppression is consistent with AQP5-mediated signaling. Inhibiting p38 with SB203580 restored barrier function and counteracted mucus hypersecretion. Nasal administration of siNEDD4 or ovAQP5 in rats relieved allergic reactions, reduced inflammatory cell infiltration, and normalized NEDD4/p-p38/AQP5 expression. Conclusions: We have identified the NEDD4-AQP5 axis as a crucial driver of AR and a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.